350 related articles for article (PubMed ID: 33206188)
21. Comparable Survival for Hepatitis C-Related Hepatocellular Carcinoma After Liver Transplantation Irrespective of Viremic Status.
Lymberopoulos P; Shaikh A; Rich NE; Benhammou JN; Kanwal F; Cholankeril G
Clin Gastroenterol Hepatol; 2023 May; 21(5):1362-1364.e1. PubMed ID: 35346850
[TBL] [Abstract][Full Text] [Related]
22. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
23. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.
Singal AG; Rich NE; Mehta N; Branch AD; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Ioannou GN; Huang A; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Kagan S; Gopal P; Wong R; Parikh ND; Murphy CC
Gastroenterology; 2019 Nov; 157(5):1253-1263.e2. PubMed ID: 31374215
[TBL] [Abstract][Full Text] [Related]
24. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
[TBL] [Abstract][Full Text] [Related]
25. DIRECT-ACTING ANTIVIRALS FOR HEPATITIS C DO NOT AFFECT THE RISK OF DEVELOPMENT OR THE OUTCOME OF HEPATOCELLULAR CARCINOMA.
Gogichaishvili L; Lobjanidze G; Tsertsvadze T; Chkhartishvili N; Jangavadze M
Georgian Med News; 2020 Sep; (306):76-81. PubMed ID: 33130651
[TBL] [Abstract][Full Text] [Related]
26. The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma.
Wang CC; Tseng KC; Tzeng IS; Kao JH
J Formos Med Assoc; 2021 Mar; 120(3):965-973. PubMed ID: 33129621
[TBL] [Abstract][Full Text] [Related]
27. Chronic hepatitis C in the Czech Republic: Forecasting the disease burden.
Fraňková S; Urbánek P; Husa P; Němeček V; Razavi H; Razavi-Shearer D; Chlíbek R; Šperl J
Cent Eur J Public Health; 2019 Jun; 27(2):93-98. PubMed ID: 31241282
[TBL] [Abstract][Full Text] [Related]
28. Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents.
Zou WY; Choi K; Kramer JR; Yu X; Cao Y; El-Serag HB; Kanwal F
Dig Dis Sci; 2019 Nov; 64(11):3328-3336. PubMed ID: 31041639
[TBL] [Abstract][Full Text] [Related]
29. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules.
Mariño Z; Darnell A; Lens S; Sapena V; Díaz A; Belmonte E; Perelló C; Calleja JL; Varela M; Rodriguez M; Rodriguez de Lope C; Llerena S; Torras X; Gallego A; Sala M; Morillas RM; Minguez B; Llaneras J; Coll S; Carrion JA; Iñarrairaegui M; Sangro B; Vilana R; Sole M; Ayuso C; Ríos J; Forns X; Bruix J; Reig M
J Hepatol; 2019 May; 70(5):874-884. PubMed ID: 30684506
[TBL] [Abstract][Full Text] [Related]
30. Hepatocellular Carcinoma Prevention in the Era of Hepatitis C Elimination.
Lazarus JV; Picchio CA; Colombo M
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762706
[TBL] [Abstract][Full Text] [Related]
31. Should we continue surveillance for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis and cured HCV infection?
Isfordink CJ; Maan R; de Man RA; van Erpecum KJ; van der Meer AJ
Eur J Intern Med; 2021 Dec; 94():6-14. PubMed ID: 34563447
[TBL] [Abstract][Full Text] [Related]
32. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
Meringer H; Shibolet O; Deutsch L
World J Gastroenterol; 2019 Aug; 25(29):3929-3940. PubMed ID: 31413528
[TBL] [Abstract][Full Text] [Related]
33. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.
Wirth TC; Manns MP
Ann Oncol; 2016 Aug; 27(8):1467-74. PubMed ID: 27226385
[TBL] [Abstract][Full Text] [Related]
34. Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents.
Mathur K; Mazhar A; Patel M; Dakhoul L; Burney H; Liu H; Nephew L; Chalasani N; deLemos A; Gawrieh S
Clin Transl Gastroenterol; 2021 Nov; 12(11):e00420. PubMed ID: 34730559
[TBL] [Abstract][Full Text] [Related]
35. Unmet Needs in the Post-Direct-Acting Antiviral Era: Hepatocarcinogenesis After Hepatitis C Virus Eradication.
Przybyszewski EM; Chung RT
J Infect Dis; 2023 Sep; 228(Suppl 3):S226-S231. PubMed ID: 37703341
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis C virus-related complications are increasing in women veterans: A national cohort study.
Kramer JR; El-Serag HB; Taylor TJ; White DL; Asch SM; Frayne SM; Cao Y; Smith DL; Kanwal F
J Viral Hepat; 2017 Nov; 24(11):955-965. PubMed ID: 28815822
[TBL] [Abstract][Full Text] [Related]
37. Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study.
Nakano M; Koga H; Ide T; Kuromatsu R; Hashimoto S; Yatsuhashi H; Seike M; Higuchi N; Nakamuta M; Shakado S; Sakisaka S; Miuma S; Nakao K; Yoshimaru Y; Sasaki Y; Oeda S; Eguchi Y; Honma Y; Harada M; Nagata K; Mawatari S; Ido A; Maeshiro T; Matsumoto S; Takami Y; Sohda T; Torimura T
Cancer Med; 2019 May; 8(5):2646-2653. PubMed ID: 30900818
[TBL] [Abstract][Full Text] [Related]
38. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
[TBL] [Abstract][Full Text] [Related]
39. The Achievement of a Sustained Virological Response Either Before or After Hepatectomy Improves the Prognosis of Patients with Primary Hepatitis C Virus-Related Hepatocellular Carcinoma.
Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Uesaka K
Ann Surg Oncol; 2019 Dec; 26(13):4566-4575. PubMed ID: 31602577
[TBL] [Abstract][Full Text] [Related]
40. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
